Q2 2025 Management View CEO David L. Hallal emphasized Scholar Rock is “scaling for the next phase of growth as a commercial stage fully integrated global biopharmaceutical company.” He outlined three ...

It didn't take a high-powered academic to figure out why Scholar Rock 's (NASDAQ: SRRK) share price swooned by more than 5% ...

No revenue was recorded as the company remains pre-commercial, in line with analyst expectations. R&D and G&A expenses surged 47% and 191% year over year as apitegromab advanced toward anticipated U.S ...

Detailed price information for Scholar Rock Holding Corp (SRRK-Q) from The Globe and Mail including charting and trades.

“Scholar Rock has entered 2025 from a position of financial strength, and the successful public offering completed in October 2024 will support both the planned commercial launch of apitegromab ...

Shares of Scholar Rock (NASDAQ: SRRK) shot 364% higher on Monday, Oct. 7, 2024. The market was reacting to surprisingly positive news regarding the clinical-stage drugmaker's lead candidate ...

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases ...

Scholar Rock's cash burn was increasing - net losses between 2020 and 2023 were $ (86.5m), $ (132m), $ (135m), and $ (166m), and its share price had declined to ~$6.5 by October 2023.

Scholar Rock's stock is down 45% in the year through Friday's close, while the S&P 500 SPX has gained 20.6%. -Ciara Linnane ...

We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where Scholar Rock Holding Corporation (NASDAQ:SRRK) stands against other ...

Scholar Rock, a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy and other severe and debilitating neuromuscular ...

The biotech company Scholar Rock reported Monday that its experimental medicine improved motor function in patients with a muscle-wasting disease called spinal muscular atrophy, paving the way for ...